New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
08:46 EDTEWEdwards Lifesciences a takeover candidate, says Canaccord
Canaccord believes the unexpected simultaneous approval of Edwards Lifesciences' SAPIEN XT heart valve and its green light for XT to treat high risk patients with severe aortic stenosis will cause Street estimates to increase. The firm views Edwards as an attractive acquisition candidate, citing its focus on a large and growing market and its high operating margins, and has a Buy rating with a $96 price target on the stock.
News For EW From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 20, 2015
05:30 EDTEWEdwards Lifesciences announces outcomes for patients treated with SAPIEN 3 valve
Edwards Lifesciences announced that 30-day outcomes for intermediate-risk patients treated transfemorally with the SAPIEN 3 transcatheter aortic valve at centers in Europe and Canada demonstrated very low mortality and stroke rates, and no severe paravalvular leaks. These independently adjudicated data are consistent with the outcomes recently reported in a similar study of 1,000 patients treated at 51 centers in the United States. In the multi-center study of 101 intermediate-risk patients, all-cause mortality was 1 percent. The frequency of other important complications was also low: the disabling stroke rate was 2 percent, major vascular complications were 2 percent and the permanent pacemaker rate was 4 percent. The investigators also noted that the SAPIEN 3 valve had excellent hemodynamic performance, with very low incidence of significant paravalvular regurgitation, as only 2.3 percent of patients had moderate paravalvular leaks and there were no reports of severe leaks.
May 19, 2015
09:21 EDTEWEdwards Lifesciences voluntarily pauses enrollment for Fortis clinical program
Subscribe for More Information
08:48 EDTEWEdwards Lifesciences reports positive results from treatment with SAPIEN 3
Subscribe for More Information
May 12, 2015
10:01 EDTEWOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:48 EDTEWEdwards Lifesciences upgraded to Overweight from Neutral at JPMorgan
JPMorgan upgraded Edwards Lifesciences to Overweight following the 15% selloff since mid-March. The firm says its confidence in the conversion of the surgical valve replacement market to transcatheter replacement increased significantly at this year's ACC. It adds that its recent field work indicates the TAVR market has accelerated post-ACC. JPMorgan raised its price target for shares to $155 from $147.
06:35 EDTEWEdwards Lifesciences upgraded to Overweight from Neutral at JPMorgan

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use